|
1
|
Muro P, Zhang L, Li S, Zhao Z, Jin T, Mao
F and Mao Z: The emerging role of oxidative stress in inflammatory
bowel disease. Front Endocrinol (Lausanne). 15:13903512024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Al-Amrah H, Saadah OI, Mosli M, Edris S,
Alhindi R and Bahieldin A: Alteration of the gut microbiome for
patients with inflammatory bowel disease: A review. Appl Ecol
Environ Res. 18:7379–7392. 2020. View Article : Google Scholar
|
|
3
|
Chew DCH, Khoo XH, Lee TS, Chin KY, Raja
Ali RA, Muhammad Nawawi KN, Wan Ibrahim NR and Hilmi I: A
systematic review on the increasing incidence of inflammatory bowel
disease in southeast asia: Looking beyond the urbanization
phenomenon. Inflamm Bowel Dis. 30:1566–1578. 2024. View Article : Google Scholar
|
|
4
|
Saleem H, Muhammad Jaffry SHB, Zia U,
Marwat ZI, Shah N and Alamzeb J: Examining the autoimmune, genetic,
environmental, and microbial aspects of the complex etiology of
inflammatory bowel diseases: A comprehensive review and comparative
analysis. J Women Med Dent Coll. 2:2024 View Article : Google Scholar
|
|
5
|
Bastaki SMA, Amir N, Adeghate E and Ojha
S: Lycopodium mitigates oxidative stress and inflammation in the
colonic mucosa of acetic Acid-induced colitis in rats. Molecules.
27:27742022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao C, Zhou Y, Chen Z, Li H, Xiao Y, Hao
W, Zhu Y, Vong CT, Farag MA, Wang Y and Wang S: Turmeric-derived
nanovesicles as novel nanobiologics for targeted therapy of
ulcerative colitis. Theranostics. 12:5596–5614. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liao HX, Mao X, Wang L, Wang N, Ocansey
DKW, Wang B and Mao F: The role of mesenchymal stem cells in
attenuating inflammatory bowel disease through ubiquitination.
Front Immunol. 15:14230692014. View Article : Google Scholar
|
|
8
|
Noguera-Fernández N, Candela-González J
and Orenes-Piñero E: Probiotics, prebiotics, fecal microbiota
transplantation, and dietary patterns in inflammatory bowel
disease. Mol Nutr Food Res. 68:e24004292024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Higashiyama M and Hokari R: New and
emerging treatments for inflammatory bowel disease. Digestion.
104:74–81. 2023. View Article : Google Scholar
|
|
10
|
Zhou M, Wang D, Li X, Cao Y, Yi C, Wiredu
Ocansey DK, Zhou Y and Mao F: Farnesoid-X receptor as a therapeutic
target for inflammatory bowel disease and colorectal cancer. Front
Pharmacol. 13:10168362022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Xu T, Zhao Y, Zhang H, Liu Z, Wang
H, Huang C, Shu Z, Gao L, Xie R, et al: Discovery and optimization
of novel nonbile acid FXR agonists as preclinical candidates for
the treatment of inflammatory bowel disease. J Med Chem.
67:5642–5661. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim HI, Park J, Zhu Y, Wang X, Han Y and
Zhang D: Recent advances in extracellular vesicles for therapeutic
cargo delivery. Exp Mol Med. 56:836–849. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Zhang Y, Dong PY, Yang GM and
Gurunathan S: A comprehensive review on the composition,
biogenesis, purification, and multifunctional role of exosome as
delivery vehicles for cancer therapy. Biomed Pharmacother.
165:1150872023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miao C, Wang X, Zhou W and Huang J: The
emerging roles of exosomes in autoimmune diseases, with special
emphasis on microRNAs in exosomes. Pharmacol Res. 169:1056802021.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ludwig N, Whiteside TL and Reichert TE:
Challenges in exosome isolation and analysis in health and disease.
Int J Mol Sci. 20:46842019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ocansey DKW, Zhang Z, Xu X, Liu L, Amoah
S, Chen X, Wang B, Zhang X and Mao F: Mesenchymal stem cell-derived
exosome mitigates colitis via the modulation of the gut
metagenomics-metabolomics-farnesoid X receptor axis. Biomater Sci.
10:4822–4836. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou M, Pei B, Cai P, Yi C, Akanyibah FA,
Lyu C and Mao F: Human umbilical cord mesenchymal stem cell-derived
exosomes repair IBD by activating the SIRT1-FXR pathway in
macrophages. Stem Cell Res Ther. 16:2332025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jella KK, Nasti TH, Li Z, Malla SR,
Buchwald ZS and Khan MK: Exosomes, their biogenesis and role in
inter-cellular communication, tumor microenvironment and cancer
immunotherapy. Vaccines (Basel). 6:692018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wani S, Man Law IK and Pothoulakis C: Role
and mechanisms of exosomal miRNAs in IBD pathophysiology. Am J
Physiol Liver Physiol. 319:G646–G654. 2020.
|
|
20
|
van Niel G, D'Angelo G and Raposo G:
Shedding light on the cell biology of extracellular vesicles. Nat
Rev Mol Cell Biol. 19:213–228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gurung S, Perocheau D, Touramanidou L and
Baruteau J: The exosome journey: From biogenesis to uptake and
intracellular signalling. Cell Commun Signal. 19:472021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matsui T, Osaki F, Hiragi S, Sakamaki Y
and Fukuda M: ALIX and ceramide differentially control polarized
small extracellular vesicle release from epithelial cells. EMBO
Rep. 22:e514752021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee KM, Seo EC, Lee JH, Kim HJ and Hwangbo
C: The multifunctional protein Syntenin-1: Regulator of exosome
biogenesis, cellular function, and tumor progression. Int J Mol
Sci. 24:94182023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim G, Zhu R, Zhang Y, Jeon H, Shirinichi
F and Wang Y: Fluorescent chiral quantum dots to unveil
Origin-dependent exosome uptake and cargo release. ACS Appl Bio
Mater. 7:3358–3374. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang M, Yadav MK, Mbanefo EC, Yu CR and
Egwuagu CE: IL-27-containing exosomes secreted by innate B-1a cells
suppress and ameliorate uveitis. Front Immunol. 14:10711622023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K,
Li T, Shen Y, Fan X, Lin F, et al: CAR exosomes derived from
effector CAR-T cells have potent antitumour effects and low
toxicity. Nat Commun. 10:43552019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang H, Chen J, Liu S, Xue Y, Li Z, Wang
T, Jiao L, An Q, Liu B, Wang J and Zhao H: Exosomes From
IgE-stimulated mast cells aggravate asthma-mediated atherosclerosis
through circRNA CDR1as-mediated endothelial cell dysfunction in
mice. Arterioscler Thromb Vasc Biol. 44:e99–e115. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu H, Zhang X, Zhang M, Zhang S, Li J,
Zhang Y, Wang Q, Cai JP, Cheng K and Wang S: Mesenchymal stem cell
derived exosomes repair uterine injury by targeting transforming
growth factor-β signaling. ACS Nano. 18:3509–3519. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin Y, Anderson JD, Rahnama LMA, Gu SV and
Knowlton AA: Exosomes in disease and regeneration: Biological
functions, diagnostics, and beneficial effects. Am J Physiol Circ
Physiol. 319:H1162–H1180. 2020. View Article : Google Scholar
|
|
30
|
Huang KY, Upadhyay G, Ahn Y, Sakakura M,
Pagan-Diaz GJ, Cho Y, Weiss AC, Huang C, Mitchell JW, Li J, et al:
Neuronal innervation regulates the secretion of neurotrophic
myokines and exosomes from skeletal muscle. Proc Natl Acad Sci USA.
121:e23135901212024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ocansey DKW, Zhang L, Wang Y, Yan Y, Qian
H, Zhang X, Xu W and Mao F: Exosome-mediated effects and
applications in inflammatory bowel disease. Biol Rev. 95:1287–1307.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kourembanas S: Exosomes: Vehicles of
intercellular signaling, biomarkers, and vectors of cell therapy.
Annu Rev Physiol. 77:13–27. 2015. View Article : Google Scholar
|
|
33
|
Chen H, Chengalvala V, Hu H and Sun D:
Tumor-derived exosomes: Nanovesicles made by cancer cells to
promote cancer metastasis. Acta Pharm Sin B. 11:2136–2149. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huber CC and Wang H: Pathogenic and
therapeutic role of exosomes in neurodegenerative disorders. Neural
Regen Res. 19:75–79. 2024. View Article : Google Scholar
|
|
35
|
Zhang Z, Zou Y, Song C, Cao K, Cai K, Chen
S, Wu Y, Geng D, Sun G, Zhang N, et al: Advances in the study of
exosomes in cardiovascular diseases. J Adv Res. 66:133–153. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Larson A, Natera-Rodriguez DE, Crane A,
Larocca D, Low WC, Grande AW and Lee J: Emerging roles of exosomes
in stroke therapy. Int J Mol Sci. 25:65072024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Singh A, Behl T, Sehgal A, Singh S, Sharma
N, Naqwi M, Mavi A and Singh R: Exploring the role of exosomes in
rheumatoid arthritis. Inflammopharmacology. 31:119–128. 2023.
View Article : Google Scholar
|
|
38
|
Gao S, Dong Y, Yan C, Yu T and Cao H: The
role of exosomes and exosomal microRNA in diabetic cardiomyopathy.
Front Endocrinol (Lausanne). 14:13274952024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hassanzadeh A, Shomali N, Kamrani A,
Nasiri H, Ahmadian Heris J, Pashaiasl M, Sadeghi M, Sadeghvand S,
Valedkarimi Z and Akbari M: Detailed role of mesenchymal stem cell
(MSC)-derived exosome therapy in cardiac diseases. EXCLI J.
23:401–420. 2024.PubMed/NCBI
|
|
40
|
Gheitasi H, Sabbaghian M, Shekarchi AA,
Mirmazhary AA and Poortahmasebi V: Exosome-mediated regulation of
inflammatory pathway during respiratory viral disease. Virol J.
21:302024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun Y, Zhang S, Shen Y, Lu H, Zhao X, Wang
X, Wang Y, Wang T, Liu B, Yao L and Wen J: Therapeutic application
of mesenchymal stem cell-derived exosomes in skin wound healing.
Front Bioeng Biotechnol. 12:14287932024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dehghan Z, Rezaee D, Noori E, Pilehchi T,
Saberi F, Taheri Z, Darya G and Mehdinejadiani S: Exosomes as
modulators of embryo implantation. Mol Biol Rep. 51:2842024.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Keerthikumar S, Chisanga D, Ariyaratne D,
Al Saffar H, Anand S, Zhao K, Samuel M, Pathan M, Jois M,
Chilamkurti N, et al: ExoCarta: A Web-Based compendium of exosomal
cargo. J Mol Biol. 428:688–692. 2016. View Article : Google Scholar :
|
|
44
|
Huang D, Chen J, Hu D, Xie F, Yang T, Li
Z, Wang X, Xiao Y, Zhong J, Jiang Y, et al: Advances in biological
function and clinical application of small extracellular vesicle
membrane proteins. Front Oncol. 11:6759402021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng D, Huo M, Li B, Wang W, Piao H, Wang
Y, Zhu Z, Li D, Wang T and Liu K: The role of exosomes and exosomal
MicroRNA in cardiovascular disease. Front Cell Dev Biol.
8:161612021. View Article : Google Scholar
|
|
46
|
Wu X, Xu X, Xiang Y, Fan D, An Q, Yue G,
Jin Z, Ding J, Hu Y, Du Q, et al: Exosome-mediated effects and
applications in inflammatory diseases of the digestive system. Eur
J Med Res. 27:1632022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guan Q: A comprehensive review and update
on the pathogenesis of inflammatory bowel disease. J Immunol Res.
2019:72472382019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lv X, Gao X, Liu J, Deng Y, Nie Q, Fan X,
Ye Z, Liu P and Wen J: Immune-mediated inflammatory diseases and
risk of venous thromboembolism: A Mendelian randomization study.
Front Immunol. 13:10427512022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kaplan GG and Ng SC: Globalisation of
inflammatory bowel disease: Perspectives from the evolution of
inflammatory bowel disease in the UK and China. Lancet
Gastroenterol Hepatol. 1:307–316. 2016. View Article : Google Scholar
|
|
50
|
Arabpour M, Saghazadeh A and Rezaei N:
Anti-inflammatory and M2 macrophage polarization-promoting effect
of mesenchymal stem cell-derived exosomes. Int Immunopharmacol.
97:1078232021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Eissa N, Hussein H and Ghia JE: A Gene
expression analysis of M1 and M2 polarized macrophages. Methods Mol
Biol. 2184:131–144. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang K, Guo J, Yan W and Xu L: Macrophage
polarization in inflammatory bowel disease. Cell Commun Signal.
21:3672023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yang R, Liao Y, Wang L, He P, Hu Y, Yuan
D, Wu Z and Sun X: Exosomes derived from M2b macrophages attenuate
DSS-induced colitis. Front Immunol. 10:23462019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lethen I, Lechner-Grimm K, Gabel M, Knauss
A, Atreya R, Neurath MF and Weigmann B: Tofacitinib affects M1-like
and M2-like polarization and tissue factor expression in
macrophages of healthy donors and IBD patients. Inflamm Bowel Dis.
30:1151–1163. 2024. View Article : Google Scholar
|
|
55
|
Mao F, Wu Y, Tang X, Wang J, Pan Z, Zhang
P, Zhang B, Yan Y, Zhang X, Qian H and Xu W: Human umbilical cord
mesenchymal stem cells alleviate inflammatory bowel disease through
the regulation of 15-LOX-1 in macrophages. Biotechnol Lett.
39:929–938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mao F, Wu Y, Tang X, Kang J, Zhang B, Yan
Y, Qian H, Zhang X and Xu W: Exosomes derived from human umbilical
cord mesenchymal stem cells relieve inflammatory bowel disease in
mice. Biomed Res Int. 2017:53567602017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Xu X, Peng J, Wang N, Ocansey DKW, Zhang X
and Mao F: hucMSC-Ex alleviates inflammatory bowel disease in mice
by enhancing M2-type macrophage polarization via the
METTL3-Slc37a2-YTHDF1 axis. Cell Biol Toxicol. 40:742024.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wei Z, Hang S, Wiredu Ocansey DK, Zhang Z,
Wang B, Zhang X and Mao F: Human umbilical cord mesenchymal stem
cells derived exosome shuttling mir-129-5p attenuates inflammatory
bowel disease by inhibiting ferroptosis. J Nanobiotechnology.
21:1882023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kowal J and Tkach M: Dendritic cell
extracellular vesicles. Int Rev Cell Mol Biol. 349:213–249. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rao Q, Ma G, Li M, Wu H, Zhang Y, Zhang C,
Ma Z and Huang L: Targeted delivery of triptolide by dendritic
cell-derived exosomes for colitis and rheumatoid arthritis therapy
in murine models. Br J Pharmacol. 180:330–346. 2023. View Article : Google Scholar
|
|
61
|
Wang L, Yu Z, Wan S, Wu F, Chen W, Zhang
B, Lin D, Liu J, Xie H, Sun X and Wu Z: Exosomes derived from
dendritic cells treated with schistosoma japonicum soluble egg
antigen attenuate DSS-induced colitis. Front Pharmacol. 8:6512017.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Elashiry M, Elashiry MM, Elsayed R,
Rajendran M, Auersvald C, Zeitoun R, Rashid MH, Ara R, Meghil MM,
Liu Y, et al: Dendritic cell derived exosomes loaded with
immunoregulatory cargo reprogram local immune responses and inhibit
degenerative bone disease in vivo. J Extracell Vesicles.
9:17953622020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Barnhoorn MC, Wasser MNJM, Roelofs H,
Maljaars PWJ, Molendijk I, Bonsing BA, Oosten LEM, Dijkstra G, van
der Woude CJ, Roelen DL, et al: Long-term evaluation of allogeneic
bone marrow-derived mesenchymal stromal cell therapy for Crohn's
disease perianal fistulas. J Crohns Colitis. 14:64–70. 2020.
View Article : Google Scholar
|
|
64
|
Stavely R, Robinson AM, Miller S, Boyd R,
Sakkal S and Nurgali K: Human adult stem cells derived from adipose
tissue and bone marrow attenuate enteric neuropathy in the
guinea-pig model of acute colitis. Stem Cell Res Ther. 6:2442015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chen J, Xie S, Qiu D, Xie M, Wu M, Li X,
Zhang X, Wu Q, Xiong Y, Wu C, et al: The NLRP3 molecule influences
the therapeutic effects of mesenchymal stem cells through
Glut1-mediated energy metabolic reprogramming. J Adv Res.
65:125–136. 2024. View Article : Google Scholar :
|
|
66
|
Li M, Zhao J, Cao M, Liu R, Chen G, Li S,
Xie Y, Xie J, Cheng Y, Huang L, et al: Mast cells-derived MiR-223
destroys intestinal barrier function by inhibition of CLDN8
expression in intestinal epithelial cells. Biol Res. 53:122020.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang S, Xu W, Wang H, Cao M, Li M, Zhao
J, Hu Y, Wang Y, Li S, Xie Y, et al: Inhibition of CREB-mediated
ZO-1 and activation of NF-κB-induced IL-6 by colonic epithelial
MCT4 destroys intestinal barrier function. Cell Prolif.
52:e126732019. View Article : Google Scholar
|
|
68
|
Chojnacki C, Wisniewska-Jarosinska M,
Walecka-Kapica E, Klupinska G, Jaworek J and Chojnacki J:
Evaluation of melatonin effectiveness in the adjuvant treatment of
ulcerative colitis. J Physiol Pharmacol. 62:327–334.
2011.PubMed/NCBI
|
|
69
|
Heidari M, Pouya S, Baghaei K, Aghdaei HA,
Namaki S, Zali MR and Hashemi SM: The immunomodulatory effects of
adipose-derived mesenchymal stem cells and mesenchymal stem
cells-conditioned medium in chronic colitis. J Cell Physiol.
233:8754–8766. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Heidari N, Abbasi-Kenarsari H, Namaki S,
Baghaei K, Zali MR, Ghaffari Khaligh S and Hashemi SM:
Adipose-derived mesenchymal stem cell-secreted exosome alleviates
dextran sulfate sodium-induced acute colitis by Treg cell induction
and inflammatory cytokine reduction. J Cell Physiol. 236:5906–5920.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen P, Huang S, Yu Q, Chao K, Wang Y,
Zhou G, Zhuang X, Zeng Z, Chen M and Zhang S: Serum exosomal
microRNA-144-3p: A promising biomarker for monitoring Crohn's
disease. Gastroenterol Rep (Oxf). 10:goab0562021. View Article : Google Scholar
|
|
72
|
Gong L, Xiao J, Yi J, Xiao J, Lu F and Liu
X: Immunomodulatory effect of serum exosomes from crohn disease on
macrophages via Let-7b-5p/TLR4 signaling. Inflamm Bowel Dis.
28:96–108. 2022. View Article : Google Scholar
|
|
73
|
Yarani R, Shojaeian A, Palasca O, Doncheva
NT, Jensen LJ, Gorodkin J and Pociot F: Differentially expressed
miRNAs in ulcerative colitis and Crohn's disease. Front Immunol.
13:8657772022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wu F, Zhang S, Dassopoulos T, Harris ML,
Bayless TM, Meltzer SJ, Brant SR and Kwon JH: Identification of
microRNAs associated with ileal and colonic Crohnʼs disease.
Inflamm Bowel Dis. 16:1729–1738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Quaglio AEV, Santaella FJ, Rodrigues MAM,
Sassaki LY and Di Stasi LC: MicroRNAs expression influence in
ulcerative colitis and Crohn's disease: A pilot study for the
identification of diagnostic biomarkers. World J Gastroenterol.
27:7801–7812. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wong W, Lee MM, Chan BD, Kam RK, Zhang G,
Lu AP and Tai WC: Proteomic profiling of dextran sulfate sodium
induced acute ulcerative colitis mice serum exosomes and their
immunomodulatory impact on macrophages. Proteomics. 16:1131–1145.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Clua-Ferré L, Suau R, Vañó-Segarra I,
Ginés I, Serena C and Manyé J: Therapeutic potential of mesenchymal
stem cellderived extracellular vesicles: A focus on inflammatory
bowel disease. Clin Transl Med. 14:e700752024. View Article : Google Scholar
|
|
78
|
Zheng X, Chen F, Zhang Q, Liu Y, You P,
Sun S, Lin J and Chen N: Salivary exosomal PSMA7: A promising
biomarker of inflammatory bowel disease. Protein Cell. 8:686–695.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhou W and Anakk S: Enterohepatic and
non-canonical roles of farnesoid X receptor in controlling lipid
and glucose metabolism. Mol Cell Endocrinol. 549:1116162022.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ramos Pittol JM, Milona A, Morris I,
Willemsen ECL, van der Veen SW, Kalkhoven E and van Mil SWC: FXR
isoforms control different metabolic functions in liver cells via
binding to specific DNA motifs. Gastroenterology.
159:1853–1865.e10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Jiang L, Zhang H, Xiao D, Wei H and Chen
Y: Farnesoid X receptor (FXR): Structures and ligands. Comput
Struct Biotechnol J. 19:2148–2159. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Vaquero J, Monte MJ, Dominguez M, Muntané
J and Marin JJG: Differential activation of the human farnesoid X
receptor depends on the pattern of expressed isoforms and the bile
acid pool composition. Biochem Pharmacol. 86:926–939. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Tian SY, Chen SM, Pan CX and Li Y: FXR:
Structures, biology, and drug development for NASH and fibrosis
diseases. Acta Pharmacol Sin. 43:1120–1132. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Stojancevic M, Stankov K and Mikov M: The
impact of Farnesoid X receptor activation on intestinal
permeability in inflammatory bowel disease. Can J Gastroenterol.
26:631–637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Gioiello A, Rosatelli E and Cerra B:
Patented farnesoid X receptor modulators: A review (2019-present).
Expert Opin Ther Pat. 34:547–564. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ocvirk S and O'Keefe SJD: Dietary fat,
bile acid metabolism and colorectal cancer. Semin Cancer Biol.
73:347–355. 2021. View Article : Google Scholar
|
|
87
|
Stofan M and Guo GL: Bile Acids and FXR:
Novel targets for liver diseases. Front Med (Lausanne). 7:5442020.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Xiang J, Zhang Z, Xie H, Zhang C, Bai Y,
Cao H, Che Q, Guo J and Su Z: Effect of different bile acids on the
intestine through enterohepatic circulation based on FXR. Gut
Microbes. 13:19490952021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Chiang JYL and Ferrell JM: Up to date on
cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis.
Liver Res. 4:47–63. 2020. View Article : Google Scholar
|
|
90
|
Fiorucci S, Baldoni M, Ricci P, Zampella
A, Distrutti E and Biagioli M: Bile acid-activated receptors and
the regulation of macrophages function in metabolic disorders. Curr
Opin Pharmacol. 53:45–54. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Cui JY, Aleksunes LM, Tanaka Y, Fu ZD, Guo
Y, Guo GL, Guo Y, Guo GL, Lu H, Zhong XB and Klaassen CD: Bile
acids via FXR initiate the expression of major transporters
involved in the enterohepatic circulation of bile acids in newborn
mice. Am J Physiol Liver Physiol. 302:G979–G996. 2012.
|
|
92
|
Fuchs CD, Krivanec S, Steinacher D, Mlitz
V, Wahlström A, Stahlman M, Claudel T, Scharnagl H, Stojakovic T,
Marschall HU and Trauner M: Absence of Bsep/Abcb11 attenuates MCD
dietinduced hepatic steatosis but aggravates inflammation in mice.
Liver Int. 40:1366–1377. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Fuchs CD and Trauner M: Role of bile acids
and their receptors in gastrointestinal and hepatic
pathophysiology. Nat Rev Gastroenterol Hepatol. 19:432–450. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jiang M, Li F, Liu Y, Gu Z, Zhang L, Lee
J, He L, Vatsalya V, Zhang HG, Deng Z, et al: Probiotic-derived
nanoparticles inhibit ALD through intestinal miR194 suppression and
subsequent FXR activation. Hepatology. 77:1164–1180. 2023.
View Article : Google Scholar
|
|
95
|
Fleishman JS and Kumar S: Bile acid
metabolism and signaling in health and disease: Molecular
mechanisms and therapeutic targets. Signal Transduct Target Ther.
9:972024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Panzitt K and Wagner M: FXR in liver
physiology: Multiple faces to regulate liver metabolism. Biochim
Biophys Acta Mol Basis Dis. 1867:1661332021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Liu Q, Yang M, Fu X, Liu R, Sun C, Pan H,
Wong CW and Guan M: Activation of farnesoid X receptor promotes
triglycerides lowering by suppressing phospholipase A2 G12B
expression. Mol Cell Endocrinol. 436:93–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Han C: Update on FXR Biology: Promising
therapeutic Target? Int J Mol Sci. 19:20692018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Clifford BL, Sedgeman LR, Williams KJ,
Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC,
Wahlström A, Ashby JW, et al: FXR activation protects against NAFLD
via bile-acid-dependent reductions in lipid absorption. Cell Metab.
33:1671–1684.e4. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Guo J, Huang S, Yi Q, Liu N, Cui T, Duan
S, Chen J, Li J, Li J, Wang L, et al: Hepatic Clstn3 ameliorates
lipid metabolism disorders in high Fat Diet-Induced NAFLD through
activation of FXR. ACS Omega. 8:26158–26169. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Xu H, Fang F, Wu K, Song J, Li Y, Lu X,
Liu J, Zhou L, Yu W, Yu F and Gao J: Gut microbiota-bile acid
crosstalk regulates murine lipid metabolism via the intestinal
FXR-FGF19 axis in diet-induced humanized dyslipidemia. Microbiome.
11:2622023. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Sonne DP: Mechanisms in endocrinology: FXR
signalling: A novel target in metabolic diseases. Eur J Endocrinol.
184:R193–R205. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hou Y, Fan W, Yang W, Samdani AQ, Jackson
AO and Qu S: Farnesoid X receptor: An important factor in blood
glucose regulation. Clin Chim Acta. 495:29–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Sinal CJ, Tohkin M, Miyata M, Ward JM,
Lambert G and Gonzalez FJ: Targeted disruption of the nuclear
receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell.
102:731–744. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lambert G, Amar MJA, Guo G, Brewer HB,
Gonzalez FJ and Sinal CJ: The Farnesoid X-receptor is an essential
regulator of cholesterol homeostasis. J Biol Chem. 278:2563–2570.
2003. View Article : Google Scholar
|
|
106
|
Lee Y, Kim BR, Kang GH, Lee GJ, Park YJ,
Kim H, Jang HC and Choi SH: The effects of PPAR agonists on
atherosclerosis and nonalcoholic fatty liver disease in
ApoE-/-FXR-/-mice. Endocrinol Metab (Seoul). 36:1243–1253. 2021.
View Article : Google Scholar
|
|
107
|
Zhang Y, Lee FY, Barrera G, Lee H, Vales
C, Gonzalez FJ, Willson TM and Edwards PA: Activation of the
nuclear receptor FXR improves hyperglycemia and hyperlipidemia in
diabetic mice. Proc Natl Acad Sci. 103:1006–1011. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Stayrook KR, Bramlett KS, Savkur RS,
Ficorilli J, Cook T, Christe ME, Michael LF and Burris TP:
Regulation of carbohydrate metabolism by the farnesoid X receptor.
Endocrinology. 146:984–991. 2005. View Article : Google Scholar
|
|
109
|
Zhao T, Wang J, He A, Wang S, Chen Y, Lu
J, Lv J, Li S, Wang J, Qian M, et al: Mebhydrolin ameliorates
glucose homeostasis in type 2 diabetic mice by functioning as a
selective FXR antagonist. Metabolism. 119:1547712021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Dehondt H, Marino A, Butruille L,
Mogilenko DA, Nzoussi Loubota AC, Chávez-Talavera O, Dorchies E,
Vallez E, Haas J, Derudas B, et al: Adipocyte-specific
FXR-deficiency protects adipose tissue from oxidative stress and
insulin resistance and improves glucose homeostasis. Mol Metab.
69:1016862023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ding L, Yang Q, Zhang E, Wang Y, Sun S,
Yang Y, Tian T, Ju Z, Jiang L, Wang X, et al: Notoginsenoside Ft1
acts as a TGR5 agonist but FXR antagonist to alleviate high fat
diet-induced obesity and insulin resistance in mice. Acta Pharm Sin
B. 11:1541–1554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Pathak P, Xie C, Nichols RG, Ferrell JM,
Boehme S, Krausz KW, Patterson AD, Gonzalez FJ and Chiang JYL:
Intestine farnesoid X receptor agonist and the gut microbiota
activate G-protein bile acid receptor-1 signaling to improve
metabolism. Hepatology. 68:1574–1588. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Shi T, Malik A, Yang vom Hofe A, Matuschek
L, Mullen M, Lages CS, Kudira R, Singh R, Zhang W, Setchell KDR, et
al: Farnesoid X receptor antagonizes macrophage-dependent licensing
of effector T lymphocytes and progression of sclerosing
cholangitis. Sci Transl Med. 14:eabi43542022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Fuchs CD, Sroda N, Scharnagl H, Gupta R,
Minto W, Stojakovic T, Liles JT, Budas G, Hollenback D and Trauner
M: Non-steroidal FXR agonist cilofexor improves cholestatic liver
injury in the Mdr2-/-mouse model of sclerosing cholangitis. JHEP
Rep. 5:1008742023. View Article : Google Scholar
|
|
115
|
Fu T, Li Y, Oh TG, Cayabyab F, He N, Tang
Q, Coulter S, Truitt M, Medina P, He M, et al: FXR mediates
ILC-intrinsic responses to intestinal inflammation. Proc Natl Acad
Sci. 119:e22130411192022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Dong X, Qi M, Cai C, Zhu Y, Li Y, Coulter
S, Sun F, Liddle C, Uboha NV and Halberg R: Farnesoid X receptor
mediates macrophage-intrinsic responses to suppress colitis-induced
colon cancer progression. JCI Insight. 9:e1704282024. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Gadaleta RM, Oldenburg B, Willemsen ECL,
Spit M, Murzilli S, Salvatore L, Klomp LW, Siersema PD, van Erpecum
KJ and van Mil SW: Activation of bile salt nuclear receptor FXR is
repressed by pro-inflammatory cytokines activating NF-κB signaling
in the intestine. Biochim Biophys Acta. 1812:851–858. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wu Q, Sun L, Hu X, Wang X, Xu F, Chen B,
Liang X, Xia J, Wang P, Aibara D, et al: Suppressing the intestinal
farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis
decreases atherosclerosis. J Clin Invest. 131:e1428652021.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
McDowell C, Farooq U and Haseeb M:
Inflammatory Bowel Disease StatPearls. 2024, Available from:
http://www.ncbi.nlm.nih.gov/pubmed/30137275.
|
|
120
|
Little RD, Jayawardana T, Koentgen S,
Zhang F, Connor SJ, Boussioutas A, Ward MG, Gibson PR, Sparrow MP
and Hold GL: Pathogenesis and precision medicine for predicting
response in inflammatory bowel disease: Advances and future
directions. eGastroenterology. 2:e1000062024. View Article : Google Scholar
|
|
121
|
Ding L, Yang L, Wang Z and Huang W: Bile
acid nuclear receptor FXR and digestive system diseases. Acta Pharm
Sin B. 5:135–144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Fiorucci S, Zampella A, Ricci P, Distrutti
E and Biagioli M: Immunomodulatory functions of FXR. Mol Cell
Endocrinol. 551:1116502022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Fu T and Dong X: Abstract 3442: FXR
mediates macrophage intrinsic responses to suppress colon cancer
progression. Cancer Res. 83(7_Suppl): S34422023. View Article : Google Scholar
|
|
124
|
Zhang L, Xie C, Nichols RG, Chan SHJ,
Jiang C, Hao R, Smith PB, Cai J, Simons MN, Hatzakis E, et al:
Farnesoid X receptor signaling shapes the gut microbiota and
controls hepatic lipid metabolism. mSystems. 1:e00070–16. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Jena PK, Sheng L, Liu HX, Kalanetra KM,
Mirsoian A, Murphy WJ, French SW, Krishnan VV, Mills DA and Wan YY:
Western Diet-induced dysbiosis in farnesoid X receptor knockout
mice causes persistent hepatic inflammation after antibiotic
treatment. Am J Pathol. 187:1800–1813. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Xu M, Shen Y, Cen M, Zhu Y, Cheng F, Tang
L, Zheng X, Kim JJ, Dai N and Hu W: Modulation of the gut
Microbiota-farnesoid X receptor axis improves deoxycholic
Acid-induced intestinal inflammation in mice. J Crohns Colitis.
15:1197–1210. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Arifuzzaman M, Won TH, Yano H, Uddin J,
Emanuel ER, Hu E, Zhang W, Li TT, Jin WB, Grier A, et al: Dietary
fiber is a critical determinant of pathologic ILC2 responses and
intestinal inflammation. J Exp Med. 221:e202321482024. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Zhao D, Cai C, Chen Q, Jin S, Yang B and
Li N: High-fat diet promotes DSS-induced ulcerative colitis by
downregulated FXR expression through the TGFB pathway. Biomed Res
Int. 2020:35161282020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Vavassori P, Mencarelli A, Renga B,
Distrutti E and Fiorucci S: The bile acid receptor FXR is a
modulator of intestinal innate immunity. J Immunol. 183:6251–6261.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Raybould HE: Gut microbiota, epithelial
function and derangements in obesity. J Physiol. 590:441–446. 2012.
View Article : Google Scholar :
|
|
131
|
Gadaleta RM, van Erpecum KJ, Oldenburg B,
Willemsen ECL, Renooij W, Murzilli S, Klomp LW, Siersema PD,
Schipper ME, Danese S, et al: Farnesoid X receptor activation
inhibits inflammation and preserves the intestinal barrier in
inflammatory bowel disease. Gut. 60:463–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Curley C, Lajczak-McGinley N, Tambuwala M,
Adorini L, Fallon C, Smyth J and Keely S: Farnesoid X receptor
activation attenuates intestinal inflammation and preserves
epithelial barrier function in vivo and in vitro. Physiology.
38:2023. View Article : Google Scholar
|
|
133
|
Abraham BP, Ahmed T and Ali T:
Inflammatory bowel disease: Pathophysiology and current therapeutic
approaches. Handb Exp Pharmacol. 239:115–146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Liu HM, Liao JF and Lee TY: Farnesoid X
receptor agonist GW4064 ameliorates lipopolysaccharide-induced
ileocolitis through TLR4/MyD88 pathway related mitochondrial
dysfunction in mice. Biochem Biophys Res Commun. 490:841–848. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Liu HM, Chang ZY, Yang CW, Chang HH and
Lee TY: Farnesoid X receptor agonist GW4064 protects
lipopolysaccharide-induced intestinal epithelial barrier function
and colorectal tumorigenesis signaling through the
αKlotho/βKlotho/FGFs pathways in mice. Int J Mol Sci. 24:169322023.
View Article : Google Scholar
|
|
136
|
Ceulemans LJ, Verbeke L, Decuypere JP,
Farré R, De Hertogh G, Lenaerts K, Jochmans I, Monbaliu D, Nevens
F, Tack J, et al: Farnesoid X receptor activation attenuates
intestinal ischemia reperfusion injury in rats. PLoS One.
12:e01693312017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Xu Y, Li D, Wu J, Zhang M, Shao X, Xu L,
Tang L, Zhu M, Ni Z, Zhang M, et al: Farnesoid X receptor promotes
renal ischaemiareperfusion injury by inducing tubular epithelial
cell apoptosis. Cell Prolif. 54:e130052021. View Article : Google Scholar
|
|
138
|
Anderson KM and Gayer CP: The
pathophysiology of farnesoid X receptor (FXR) in the GI Tract:
Inflammation, barrier function and innate immunity. Cells.
10:32062021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
O'Guinn ML, Handler DA, Hsieh JJ,
Mallicote MU, Feliciano K and Gayer CP: FXR deletion attenuates
intestinal barrier dysfunction in murine acute intestinal
inflammation. Am J Physiol Liver Physiol. 327:G175–G187. 2024.
|
|
140
|
Tang K, Kong D, Peng Y, Guo J, Zhong Y, Yu
H, Mai Z, Chen Y, Chen Y, Cui T, et al: Ginsenoside Rc attenuates
DSS-induced ulcerative colitis, intestinal inflammatory, and
barrier function by activating the farnesoid X receptor. Front
Pharmacol. 13:10004442022. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Safari F, Sharifi M, Talebi A, Mehranfard
N and Ghasemi M: Alleviation of cholestatic liver injury and
intestinal permeability by lubiprostone treatment in bile duct
ligated rats: Role of intestinal FXR and tight junction proteins
claudin-1, claudin-2, and occludin. Naunyn Schmiedebergs Arch
Pharmacol. 396:2009–2022. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Comito D and Romano C: Dysbiosis in the
pathogenesis of pediatric inflammatory bowel diseases. Int J
Inflam. 2012:6871432012.PubMed/NCBI
|
|
143
|
Caenepeel C, Falony G, Machiels K,
Verstockt B, Goncalves PJ, Ferrante M, Sabino J, Raes J,
Vieira-Silva S and Vermeire S: Dysbiosis and associated stool
features improve prediction of response to biological therapy in
inflammatory bowel disease. Gastroenterology. 166:483–495
|
|
144
|
Lan J, Zhang Y, Jin C, Chen H, Su Z, Wu J,
Ma N, Zhang X, Lu Y, Chen Y, et al: Gut dysbiosis drives
inflammatory bowel disease through the CCL4L2-VSIR axis in glycogen
storage disease. Adv Sci (Weinh). 11:e23094712024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Cao Z, Fan D, Sun Y, Huang Z, Li Y, Su R,
Zhang F, Li Q, Yang H, Zhang F, et al: The gut ileal mucosal virome
is disturbed in patients with Crohn's disease and exacerbates
intestinal inflammation in mice. Nat Commun. 15:16382024.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Collins SL, Stine JG, Bisanz JE, Okafor CD
and Patterson AD: Bile acids and the gut microbiota: Metabolic
interactions and impacts on disease. Nat Rev Microbiol. 21:236–247.
2023. View Article : Google Scholar
|
|
147
|
Tian Y, Gui W, Koo I, Smith PB, Allman EL,
Nichols RG, Rimal B, Cai J, Liu Q and Patterson AD: The microbiome
modulating activity of bile acids. Gut Microbes. 11:979–996. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Dong LN, Wang M, Guo J and Wang JP: Role
of intestinal microbiota and metabolites in inflammatory bowel
disease. Chin Med J (Engl). 132:1610–1614. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Das P, Marcišauskas S, Ji B and Nielsen J:
Metagenomic analysis of bile salt biotransformation in the human
gut microbiome. BMC Genomics. 20:5172019. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Fitzpatrick LR and Jenabzadeh P: IBD and
bile acid absorption: Focus on Pre-clinical and clinical
observations. Front Physiol. 11:5642020. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Ceulemans LJ, Canovai E, Verbeke L,
Pirenne J and Farré R: The expanding role of the bile acid receptor
farnesoid X in the intestine and its potential clinical
implications. Acta Chir Belg. 116:156–163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Biet F, Locht C and Kremer L:
Immunoregulatory functions of interleukin 18 and its role in
defense against bacterial pathogens. J Mol Med. 80:147–162. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Ding JW, Andersson R, Soltesz V, Willén R
and Bengmark S: The role of bile and bile acids in bacterial
translocation in obstructive jaundice in rats. Eur Surg Res.
25:11–19. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Lorenzo-Zúñiga V, Bartolí R, Planas R,
Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA,
Ausina V, et al: Oral bile acids reduce bacterial overgrowth,
bacterial translocation, and endotoxemia in cirrhotic rats.
Hepatology. 37:551–557. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Xu X, Ocansey DKW, Hang S, Wang B, Amoah
S, Yi C, Zhang X, Liu L and Mao F: The gut metagenomics and
metabolomics signature in patients with inflammatory bowel disease.
Gut Pathog. 14:262022. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Hua Y, Jia Y, Zhang X, Yuan Z, Ji P, Hu J
and Wei YM: Baitouweng tang ameliorates DSS-induced ulcerative
colitis through the regulation of the gut microbiota and bile acids
via pathways involving FXR and TGR5. Biomed Pharmacother.
137:1113202021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Shen J, Qi Q, Han D, Lu Y, Huang R, Zhu Y,
Zhang LS, Qin XD, Zhang F, Wu HG and Liu HR: Moxibustion improves
experimental colitis in rats with Crohn's disease by regulating
bile acid enterohepatic circulation and intestinal farnesoid X
receptor. J Integr Med. 21:194–204. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Wilson A, Almousa A, Teft WA and Kim RB:
Attenuation of bile acid-mediated FXR and PXR activation in
patients with Crohn's disease. Sci Rep. 10:18662020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Chen L, Jiao T, Liu W, Luo Y, Wang J, Guo
X, Tong X, Lin Z, Sun C, Wang K, et al: Hepatic cytochrome P450 8B1
and cholic acid potentiate intestinal epithelial injury in colitis
by suppressing intestinal stem cell renewal. Cell Stem Cell.
29:1366–1381.e9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Fiorucci S, Carino A, Baldoni M, Santucci
L, Costanzi E, Graziosi L, Distrutti E and Biagioli M: Bile acid
signaling in inflammatory bowel diseases. Dig Dis Sci. 66:674–693.
2021. View Article : Google Scholar :
|
|
161
|
Zhang H, Wang L, Li C, Yu Y, Yi Y, Wang J
and Chen D: Exosome-induced regulation in inflammatory bowel
disease. Front Immunol. 10:14642019. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ma F, Zhang S, Akanyibah FA, Zhang W, Chen
K, Ocansey DKW, Lyu C and Mao F: Exosome-mediated macrophage
regulation for inflammatory bowel disease repair: A potential
target of gut inflammation. Am J Transl Res. 15:6970–6987.
2023.
|
|
163
|
Lin S, Wang S, Wang P, Tang C, Wang Z,
Chen L, Luo G, Chen H, Liu Y, Feng B, et al: Bile acids and their
receptors in regulation of gut health and diseases. Prog Lipid Res.
89:1012102023. View Article : Google Scholar
|
|
164
|
Li Y, Li H, Cui M, Zhou Y and Zhang M and
Zhang M: Interaction of exosomal MicroRNA and oxidative stress in
the pathogenesis of Colitis-associated cancer. Front Biosci
(Landmark Ed). 29:2762024. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Al-Sadi R, Engers J and Abdulqadir R: Talk
about micromanaging! Role of microRNAs in intestinal barrier
function. Am J Physiol Liver Physiol. 319:G170–G14. 2020.
|
|
166
|
Gu L, Ren F, Fang X, Yuan L, Liu G and
Wang S: Exosomal MicroRNA-181a derived from mesenchymal stem cells
improves gut microbiota composition, barrier function, and
inflammatory status in an experimental colitis model. Front Med
(Lausanne). 8:6606142021. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Gao F, Wu S, Zhang K, Xu Z, Zhang X, Zhu Z
and Quan F: Goat milk exosomes ameliorate ulcerative colitis in
mice through modulation of the intestinal barrier, gut microbiota,
and metabolites. J Agric Food Chem. 72:23196–23210. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Jin J, Jung M, Sonn SK, Seo S, Suh J,
Kweon HY, Moon SH, Jo H, Yoon NH and Oh GT: Peroxiredoxin 3
deficiency exacerbates DSS-induced acute colitis via exosomal
miR-1260b-Mediated barrier disruption and proinflammatory
signaling. Antioxid Redox Signal. 42:133–149. 2025. View Article : Google Scholar
|
|
169
|
Chang X, Song Y, Xia T, He Z, Zhao S, Wang
ZJ, Gu L, Li ZS, Xu C, Wang SL and Bai Y: Macrophage-derived
exosomes promote intestinal mucosal barrier dysfunction in
inflammatory bowel disease by regulating TMIGD1 via mircroRNA-223.
Int Immunopharmacol. 121:1104472023. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Liu F, Ai F, Tang A, Yang Z, Li Z and Liu
S: Macrophage-derived exosomes promoted the development and
stemness of inflammatory bowel Disease-related colorectal cancer
via nuclear paraspeckle assembly transcript 1-Mediated
miRNA-34a-5p/phosphoprotein enriched in astrocytes 15 Axis. Inflamm
Bowel Dis. 31:524–538. 2025. View Article : Google Scholar
|
|
171
|
Liang Y, Duan L, Lu J and Xia J:
Engineering exosomes for targeted drug delivery. Theranostics.
11:3183–3195. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Alexander M and O'Connell R: Exosomal
miRNAs regulate inflammatory responses (IRM11P.624). J Immunol.
194(1_Suppl): S132.32015. View Article : Google Scholar
|
|
173
|
Alexander M, Hu R, Runtsch MC, Kagele DA,
Mosbruger TL, Tolmachova T, Seabra MC, Round JL, Ward DM and
O'Connell RM: Exosome-delivered microRNAs modulate the inflammatory
response to endotoxin. Nat Commun. 6:73212015. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Liang X, Li C, Song J, Liu A, Wang C, Wang
W, Kang Y, Sun D, Qian J and Zhang X: HucMSC-exo promote mucosal
healing in experimental colitis by accelerating intestinal stem
cells and epithelium regeneration via wnt signaling pathway. Int J
Nanomedicine. 18:2799–2818. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Yu H, Yang X, Xiao X, Xu M, Yang Y, Xue C,
Li X, Wang S and Zhao RC: Human adipose mesenchymal stem
Cell-derived exosomes protect mice from DSS-Induced inflammatory
bowel disease by promoting Intestinal-stem-cell and epithelial
regeneration. Aging Dis. 12:14232021. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Al-Madhagi H: The landscape of exosomes
biogenesis to clinical applications. Int J Nanomedicine.
19:3657–3675. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Kurian TK, Banik S, Gopal D, Chakrabarti S
and Mazumder N: Elucidating methods for isolation and
quantification of exosomes: A review. Mol Biotechnol. 63:249–266.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Lopez-Santalla M and Garin MI: Improving
the efficacy of mesenchymal Stem/Stromal-based therapy for
treatment of inflammatory bowel diseases. Biomedicines. 9:15072021.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Jang H, Kim H, Kim EH, Han G, Jang Y, Kim
Y, Lee JW, Shin SC, Kim EE, Kim SH and Yang Y: Post-insertion
technique to introduce targeting moieties in milk exosomes for
targeted drug delivery. Biomater Res. 27:1242023. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Choi H, Choi Y, Yim HY, Mirzaaghasi A, Yoo
JK and Choi C: Biodistribution of exosomes and engineering
strategies for targeted delivery of therapeutic exosomes. Tissue
Eng Regen Med. 18:499–511. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Liu H, Liang Z, Wang F, Zhou C, Zheng X,
Hu T, He X, Wu X and Lan P: Exosomes from mesenchymal stromal cells
reduce murine colonic inflammation via a macrophage-dependent
mechanism. JCI Insight. 4:e1312732019. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Baghaei K, Tokhanbigli S, Asadzadeh H,
Nmaki S, Reza Zali M and Hashemi SM: Exosomes as a novel cell-free
therapeutic approach in gastrointestinal diseases. J Cell Physiol.
234:9910–9926. 2019. View Article : Google Scholar
|
|
183
|
Kim DH, Kothandan VK, Kim HW, Kim KS, Kim
JY, Cho HJ, Lee YK, Lee DE and Hwang SR: Noninvasive assessment of
exosome pharmacokinetics in vivo: A review. Pharmaceutics.
11:6492019. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Willms E, Johansson HJ, Mäger I, Lee Y,
Blomberg KEM, Sadik M, Alaarg A, Smith CI, Lehtiö J, El Andaloussi
S, et al: Cells release subpopulations of exosomes with distinct
molecular and biological properties. Sci Rep. 6:225192016.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Shukla S, Currim F and Singh R: Do
different exosome biogenesis pathways and selective cargo
enrichment contribute to exosomal heterogeneity? Biol Cell.
115:e22001162023. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Ferguson SW and Nguyen J: Exosomes as
therapeutics: The implications of molecular composition and
exosomal heterogeneity. J Control Release. 228:179–190. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Willms E, Cabañas C, Mäger I, Wood MJA and
Vader P: Extracellular vesicle heterogeneity: Subpopulations,
isolation techniques, and diverse functions in cancer progression.
Front Immunol. 9:7382018. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Morrissey SM, Zhang F, Ding C,
Montoya-Durango DE, Hu X, Yang C, Wang Z, Yuan F, Fox M, Zhang HG,
et al: Tumor-derived exosomes drive immunosuppressive macrophages
in a pre-metastatic niche through glycolytic dominant metabolic
reprogramming. Cell Metab. 33:2040–2058.e10. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Bhatia R, Chang J, Munoz JL and Walker ND:
Forging new therapeutic targets: Efforts of tumor derived exosomes
to prepare the Pre-metastatic niche for cancer cell dissemination
and dormancy. Biomedicines. 11:16142023. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Bai S, Wei Y, Liu R, Xu R, Xiang L and Du
J: Role of tumour-derived exosomes in metastasis. Biomed
Pharmacother. 147:1126572022. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Truong NC, Huynh TN, Pham KD and Pham P:
The role of tumor-derived exosomes in tumor immune escape: A
concise review. Biomed Res Ther. 7:4132–4137. 2020. View Article : Google Scholar
|
|
192
|
Witwer KW and Wolfram J: Extracellular
vesicles versus synthetic nanoparticles for drug delivery. Nat Rev
Mater. 6:103–106. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Kimiz-Gebologlu I and Oncel SS: Exosomes:
Large-scale production, isolation, drug loading efficiency, and
biodistribution and uptake. J Control Release. 347:533–543. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Palakurthi SS, Shah B, Kapre S, Charbe N,
Immanuel S, Pasham S, Thalla M, Jain A and Palakurthi S: A
comprehensive review of challenges and advances in exosome-based
drug delivery systems. Nanoscale Adv. 6:5803–5826. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Xia Y, Zhang J, Liu G and Wolfram J:
Immunogenicity of extracellular vesicles. Adv Mater.
36:e24031992024. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Zhu X, Badawi M, Pomeroy S, Sutaria DS,
Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle K, et al:
Comprehensive toxicity and immunogenicity studies reveal minimal
effects in mice following sustained dosing of extracellular
vesicles derived from HEK293T cells. J Extracell Vesicles.
6:13247302017. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Gehrmann U, Näslund TI, Hiltbrunner S,
Larssen P and Gabrielsson S: Harnessing the exosome-induced immune
response for cancer immunotherapy. Semin Cancer Biol. 28:58–67.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Aslan C, Kiaie SH, Zolbanin NM, Lotfinejad
P, Ramezani R, Kashanchi F and Jafari R: Exosomes for mRNA
delivery: A novel biotherapeutic strategy with hurdles and hope.
BMC Biotechnol. 21:202021. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Wang J, Chen D and Ho EA: Challenges in
the development and establishment of exosome-based drug delivery
systems. J Control Release. 329:894–906. 2021. View Article : Google Scholar
|
|
200
|
Zhang Y, Bi J, Huang J, Tang Y, Du S and
Li P: Exosome: A review of its classification, isolation
techniques, storage, diagnostic and targeted therapy applications.
Int J Nanomedicine. 15:6917–6934. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Ball R, Bajaj P and Whitehead K: Achieving
long-term stability of lipid nanoparticles: Examining the effect of
pH, temperature, and lyophilization. Int J Nanomedicine.
12:305–315. 2016. View Article : Google Scholar
|
|
202
|
Lu L, Han C, Wang M, Du H, Chen N, Gao M,
Wang N, Qi D, Bai W, Yin J, et al: Assessment of bovine milk
exosome preparation and lyophilized powder stability. J Extracell
Biol. 3:e700092024. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Kheradmand F, Yasaman Rahimzadeh SF,
Esmaeili SA, Negah SS, Farkhad NK, Nazari SE, Nazari SE, Hajinejad
M, Khodadoust MA, Fadaee A, et al: Efficacy of umbilical
cord-derived mesenchymal stem cells and exosomes in conjunction
with standard IBD drug on immune responses in an IBD mouse model.
Stem Cell Res Ther. 16:52025. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Yang S, Liang X, Song J, Li C, Liu A, Luo
Y, Ma H, Tan Y and Zhang X: A novel therapeutic approach for
inflammatory bowel disease by exosomes derived from human umbilical
cord mesenchymal stem cells to repair intestinal barrier via TSG-6.
Stem Cell Res Ther. 12:3152021. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Yang X, Meng S, Jiang H, Chen T and Wu W:
Exosomes derived from interleukin-10-treated dendritic cells can
inhibit trinitrobenzene sulfonic acid-induced rat colitis. Scand J
Gastroenterol. 45:1168–1177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Kou Y, Li J, Zhu Y, Liu J, Ren R, Jiang Y,
Wang Y, Qiu C, Zhou J, Yang Z, et al: Human amniotic epithelial
stem cells promote colonic recovery in experimental colitis via
exosomal MiR-23a-TNFR1-NF-κB signaling. Adv Sci (Weinh).
11:e24014292024. View Article : Google Scholar
|
|
207
|
Park N, Kim KS, Park CG, Jung HD, Park W
and Na K: Adipose-derived stem cell-based anti-inflammatory
paracrine factor regulation for the treatment of inflammatory bowel
disease. J Control Release. 374:384–399. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Guo J, Wang F, Hu Y, Luo Y, Wei Y, Xu K,
Zhang H, Liu H, Bo L, Lv S, et al: Exosome-based bone-targeting
drug delivery alleviates impaired osteoblastic bone formation and
bone loss in inflammatory bowel diseases. Cell Reports Med.
4:1008812023. View Article : Google Scholar
|
|
209
|
Liu C, Yan X, Zhang Y, Yang M, Ma Y, Zhang
Y, Xu Q, Tu K and Zhang M: Oral administration of turmeric-derived
exosome-like nanovesicles with anti-inflammatory and pro-resolving
bioactions for murine colitis therapy. J Nanobiotechnology.
20:2062022. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Swaroop S, Vuyyuru SK, Kante B, Kumar P,
Mundhra SK, Arora U, Goyal A, Kandasamy D, Sharma R, Kabilan K, et
al: A phase I/II clinical trial of ex-vivo expanded human bone
marrow derived allogeneic mesenchymal stromal cells in adult
patients with perianal fistulizing Crohn's Disease. Stem Cell Res
Ther. 15:1402024. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Lightner AL, Reese J, Ream J, Nachand D,
Jia X, Dadgar N, Steele SR and Hull T: A Phase IB/IIA study of ex
vivo expanded allogeneic bone marrow derived mesenchymal stem cells
for the treatment of perianal fistulizing Crohn's disease. Dis
Colon Rectum. 66:1359–1372. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Lightner AL, Otero-Pineiro A, Reese J,
Ream J, Nachand D, Adams AC, VanDenBossche A and Kurowski JA: A
Phase I study of ex vivo expanded allogeneic bone marrow-derived
mesenchymal stem cells for the treatment of pediatric perianal
Fistulizing Crohn's disease. Inflamm Bowel Dis. 29:1912–1919. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Hadizadeh A, Akbari Asbagh R,
Heirani-Tabasi A, Soleimani M, Gorovanchi P, Ebrahimi Daryani N,
Vahedi A, Nazari H, Banikarimi SP, Abbaszade Dibavar M, et al:
Localized administration of mesenchymal stem cell-derived exosomes
for the treatment of refractory perianal fistula in patients with
Crohn's disease: A Phase II clinical trial. Dis Colon Rectum.
67:1564–1575. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Keung C, Nguyen TC, Lim R, Gerstenmaier A,
Sievert W and Moore GT: Local fistula injection of allogeneic human
amnion epithelial cells is safe and well tolerated in patients with
refractory complex perianal Crohn's disease: A phase I open label
study with long-term follow up. EBioMedicine. 98:1048792023.
View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Nazari H, Alborzi F, Heirani-Tabasi A,
Hadizadeh A, Asbagh RA, Behboudi B, Fazeli MS, Rahimi M, Keramati
MR, Keshvari A, et al: Evaluating the safety and efficacy of
mesenchymal stem cell-derived exosomes for treatment of refractory
perianal fistula in IBD patients: Clinical trial phase I.
Gastroenterol Rep (Oxf). 10:goac0752022. View Article : Google Scholar : PubMed/NCBI
|
